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 Abstract 
 
The sociological impact of neurodegenerative diseases, such as Alzheimer’s Disease 
(AD), places a heavy burden on the healthcare industry, patients and families, not only from a 
medical and financial impact, but also in terms of quality of life. The consequences to the 
patient, family and caregivers can be life-changing, yet quantitative studies have been sparse. 
Our understanding of ways to improve cognition in these patients would be highly beneficial. 
One such potential tool to improve cognition in these patients, the lynx1 gene, has been 
identified. The purpose of this project is to compare the effects of the lynx1 gene on Alzheimer's 
development in different genetic variant mice (wildtype, knockout, and heterozygous 
genotypes).To do this, mice underwent fear conditioned learning via the Chronic Social Defeat 
Stress (CSDS) paradigm. Based on the results from these behavioral tests, as well as predicted 
data for planned experiments, I believe that an introductory case for further studies of the 
relationship between the lynx1 gene and AD has been shown.  
 
 
 
 
 
 
 
 
 Introduction 
 
 AD is a neurodegenerative disorder, with a distinct pathology, characterized by plaques and 
neurofibrillary tangles containing aggregated -amyloid (A) and hyperphosphorylated tau protein 
(Thomsen 2016, Alud 2002). It has been shown that soluble A species are considered to be the 
most toxic form of A and are associated with cognitive deficits in AD (Thomsen 2016), including 
progressive neuronal loss, inflammation, and the gradual and inevitable decline of memory and 
cognition8. AD  is the most common cause of dementia and is currently estimated to affect more 
than 5 million people in the United States, with an expected increase to 13 million by the year 
2050. The costs of care of patients with Alzheimer’s disease in 2010 were estimated at more than 
$172 billion in the United States, an annual cost that is predicted to increase to a trillion dollars by 
205018,19.  
To date the most effective treatment for AD symptoms are Cholinesterase Inhibitors (CIs). 
Studies have shown that cholinergic systems in the basal forebrain are affected early in the disease 
process, resulting in a loss of acetylcholine neurons and loss of enzymatic function for 
acetylcholine synthesis and degradation. This in turn causes memory loss and deterioration of other 
cognitive and noncognitive functions such as neuropsychiatric symptoms9. Despite the initial 
benefit they provide, the efficacy of CIs dissipate after 6-12 months4. It is proposed that the  lynx1 
gene could be a potential tool for improved cognition and pathology improvement in AD patients.  
Lynx1 is a protein that is part of the Ly-6/neurotoxin family and is a glycophosphatidylinositol-
anchored membrane protein. Lynx1 has been shown to have several functions in the brain, 
particularly in learning and memory via inhibitory modulation on nAChR function, with high 
affinity for 7 and 42 subunit binding7. It has been shown that co-expression of lynx1 results in 
reduced agonist sensitivity and slower recovery from nACh desensitization  and that lynx1 exhibits 
inhibitory function during the critical period on nAChRs in different areas of the brain5,7. The lynx1 
gene is highly concentrated in the Pre-Frontal Cortex (PFC) and the CA1 neurons of the 
hippocampus, which are the brain areas critically impacted during AD pathology5. In addition, 
studies have also shown that the lynx1 gene competes with A1-42 plaques in binding with nicotine 
receptors, with both showing preferential binding to the 7 and 42  subunits of nAChRs2,8. 
Notably, it has been shown that the knockout of the lynx1 gene can lead to neurotoxicity and 
proliferation of the toxic effects of A1-42 plaques in the brain. The key figures from these studies 
are discussed below in greater detail. 
 
Precedential Data 
 
 Figure 1: Ws-lynx1 actively competes with oligomeric A1-42 plaques to bind/modulate 
nAChRs 
 
Previous studies have shown that both lynx1 and A1-42  plaques have a strong binding affinity to 
the 7 subunit of the nACh 
receptors2,7,11, however, it had 
not been determined how or if 
lynx1 interacts with A1-42  
plaques in regard to binding to 
the 7 subunit of nAChRs. 
Studies conducted by Thomsen 
et al.20 determined that preincubation of rat cortex tissue with 200 nM of oligomeric A1-42  plaques 
significantly decreased the amount of nAChR subunits isolated by affinity purification with Ws-
lynx1 (Figures 2A and 2B). Furthermore, preincubation of rat cortex tissues with 10 nM of Ws-
lynx1 reduced the amount of 7, 4 and 2 subunits attached to oligomeric A1-42  plaques post-
affinity purification assay (Figure 2D and 2E). These data clearly demonstrate that lynx1 competes 
with oligomeric A1-42  plaques to bind to nAChRs. 
 
Figure 2: Ws-lynx1 prevents A1-42  induced cytotoxicity 
 Another key hypothesis explored20 was that Ws-lynx1 prevented 
A1-42  induced cytotoxicity on nAChRs in vitro. Mouse cortical 
neurons were incubated with Ws-lynx1 (0.01e10 mM) for 2 hours 
followed by addition of 20 mM oligomeric A1-42 for an 
additional 24 hours. The release of lactate dehydrogenase (LDH) 
to the media was used as a measure of cytotoxicity, and the overall 
experiment resulted in significantly decreased levels of LDH release by mouse cortical neurons 
where Ws-lynx1 was expressed compared to when only oligomeric A1-42 plaques were expressed 
(Figure 3). 
 
 
 
 
 
 
Figure 3: Enhancement of Associative Learning Ability in lynx1 Null Mutant Mice 
Observed in Fear-Conditioning Assays  
It has been determined in previous studies that nAChR activation has been shown to be an 
important component of specific aspects of learning and memory3,6. Therefore, due to the fact 
that lynx1 directly modulates nAChRs, it was hypothesized that manipulation of  lynx1 would 
have significant effects on learning and 
memory. To test this, behavioral tests 
conducted by Miwa et al7. were run on 
lynx1KO mice to evaluate their learning 
abilities compared to lynx1 wildtype variant 
mice. It was determined that both lynx1KO 
mice and lynx1 wildtype variant mice did 
not behave differently in regard to novel 
contextual response and tone (Figure 4A), 
nor did lynx1KO mice show significant differences to lynx1 wildtype variant mice in regard to 
latency to enter a light/dark box (Figure 4B) or in training and location time for the hidden 
platform in the Morris water maze (Figure 4C). Therefore, it was demonstrated that lynx1 doesn’t 
display a significant change in contextual learning between lynx1KO and wildtype mice.  
 
 
Figure 4: Enhancements in Nicotine-Mediated Motor Learning Performance is expressed 
in lynx1 Null Mutant Mice  
Comparatively, when nicotine was introduced to lynx1KO and wildtype mice in relation to motor 
coordination and learning, lynx1KO mice 
showed significantly improved motor 
training compared to lynx1 wildtype mice 
that received a placebo or nicotine and 
placebo (Figure 5D). This data is 
consistent with the hypothesis that that 
elimination of lynx1 alters nAChRs 
toward heightened receptor sensitivity6.   
Based on these findings, the purpose of this project was to determine if manipulation of the 
lynx1 gene reduces A1-42  plaque and tau protein tangle levels and improves cognition in 
genetically variant mice.  
 
Hypothesis  
The hypothesis for this project was that  lynx1 knockout variant mice would have increased 
learning but altered pathology development via heightened levels of present A1-42 plaque and tau 
protein tangles, lynx1 wildtype variant mice would have decreased learning abilities but greater 
protection against A1-42 plaque and tau protein pathology development, and lynx1 heterozygous 
variant mice would have greater learning abilities and protection against levels of A1-42 plaque 
and tau protein tangle pathology development.  
  
Material and Methods  
 
Behavioral Testing Lynx1 variant mice underwent fear cue conditioning testing to examine 
variation in fear learning between genotypes. For the experimental setup, mice underwent an 
acclimation to a novel environment followed by two tone-shock pairings. The following day 
mice underwent a cued test which consisting of a two-minute time period without any sound 
followed by a two-minute sound (same sound as day 1). The context was changed between each 
day. Data collected was the percent freezing to sound. Any mouse that froze over 90% or below 
30% was not included. 
 
Histological Staining Histological analyses was to be carried out on a total of 25 mice, 23 test 
mice and two control mice (aged 6 months, both lynx1 knockout variant mice). Each genotype 
group was broken down into two age groups: one group 12-14 months of age at the time of 
histological analysis and another group 16-18 months of age. This was to compare the levels of 
AD pathology in the brain and to serve as a control for one another. Initially two stains were 
planned to be utilized, the Campbell-Switzer Silver stain to image the A1-42 plaques present in 
the brain, and an AT8 monoclonal antibody (mouse) to image levels of tau protein tangles. 
However, due to time and cost only the AT8 monoclonal antibody (mouse) was planned to be 
utilized. The protocol for AT8 immunochemistry staining protocol was planned to be based off 
of the one used by Liu et. al., 201215. Both stains would have focused on the PFC and 
hippocampus, as these are the two brain areas immediately affected by the development of AD 
pathology and express the highest concentration of lynx1 in the brain. 
Data and Interpretation of Results 
 
Lynx1KO Mice showed increased Freezing Percentage to sound compared to lynx1 
wildtype and heterozygous mice 
 
Percent freezing to sound. Lynx1KO mice displayed increased freezing to sound during the CSDS paradigm. This effect is diminished in 
lynx1 wildtype variant mice. L2KO and L1L2 DKO (double knock out) were used as controls. Data was collected from a previous study, 
none of the mice used for histology underwent this behavioral testing paradigm. 
 
As predicted, the lynx1KO mice displayed increased percent freezing to sound compared 
to lynx1 wildtype and heterozygous mice, suggesting that the lynx1KO mice experienced altered 
cognition due to deletion of the lynx1 gene. A possible explanation for this is that the increase in 
acetylcholine accessed by the nAChRs as a result of the loss of lynx1 inhibitory modulation 
resulted in increased neural plasticity6. Interestingly, the lynx1 heterozygous variant mice also 
experienced heighted levels of percent freezing to sound, implying that these mice also 
experienced some level of altered neural cognition. A possible explanation for this is that in these 
lynx1 heterozygous variant mice acetylcholine was able to leak into the nAChRs due to the lynx1 
gene being defective as a result of misappropriate binding to the nAChRs resulting in increased 
neural plasticity. Further experiments will need to be done to assess these predictions. 
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 Predicted Data and Future Experiments 
 
Predicted Histological Data 
Unfortunately due to unforeseen circumstances, the histological portion of the project could not 
be completed. However, based on previous studies conducted as well as the behavioral data 
collected for this project, it could be postulated that the following result histological results would 
occur: lynx1KO variant mice will show more expansive AD pathology development; Lynx1 
wildtype variant mice will show reduced AD pathology development. Lynx1KO variant mice will 
likely show increased AD pathology because the lynx1gene is not present to compete with A1-42 
plaque to bind to nAChRs. Examples of this can been seen in Figures 1 and 2 in the Precedential 
Experimental Data Section. Heterozygous lynx1 variant mice will likely show lower levels of AD 
pathology development similar to that of lynx1 wildtype mice, likely because while defective, the 
lynx1 gene is still present in heterozygous mice and can still express some form of binding 
competition with A1-42 plaques. 
 
 
 
 
 
 
Future Experiments and Further Directions of Study 
One potential area of future research that could be explored in relation to this project is better 
elucidating the binding affinity relationship between the lynx1 gene and the 7 subunit of nAChRs. 
Structurally, the lynx1 gene is a protoxin variant with similar three finger fold binding mechanisms 
to that of -bungarotoxin5,8. However unlike -bungarotoxin, lynx1 does not bind irreversibly to 
nAChRs. It has been determined that the lynx1 gene has three functional conformational states: 
open, closed, and desensitized. Previous studies have determined the structure of ws-lynx1 and 
have postulated that the C-loop is a key structure in relation to correct binding affinity between 
lynx1 and nAChRs17. Specifically, the movement of the C-loop is critical for correct agonist 
binding from the closed to the open state. Previous studies have shown that the interactions 
between the C loop and that low stoichiometry binding at the 4: 4 interface on the 42 subunit 
of nAChRs are of significant importance. Based on these studies it has been determined that the 
following residues on the C-loop are of particular interest for study: Arg38, Trp156 and Tyr20416. 
In addition, as previously noted, both the lynx1 gene and A1-42 plaques demonstrate preferential 
binding to the 7 and 42  subunits of nAChRs with similar binding affinities2,8 . Based on these 
precedents, could be hypothesized that there are specific residues between the lynx1 gene and the 
7 subunit that will be critical for correct binding affinity, and lack of these residues would cause 
misappropriate binding. If the case, this would provide a potential mechanism for the increased 
cognition and protection against AD pathology predicted to be demonstrated in heterozygous lynx1 
variant mice12,13,14   
In addition, several more iterations of the behavioral assessment/histological study done 
for this project should be conducted to demonstrate a more concrete relationship between the lynx1 
gene and its cognitive and biological effects on AD pathology. A more robust design that could be 
utilized in the future is to run behavioral assessments on the same mice that will be utilized in the 
histological study.  
 
Conclusion 
Overall, this project illuminated a potential relationship between the lynx1 gene and AD 
pathology progression. While introductory in scope, this project has the potential to be a valuable 
first step for future AD research via better understanding of upstream mechanisms involved in the 
development of AD pathology (via exploration of the lynx1 gene and its function within the 
cholinergic system) and illuminate a possible avenue for improved treatment via providing 
potential targets for genetic or pharmacological study in regard to AD treatment.  
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